18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 18,358 shares of the company's stock, valued at approximately $532,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. TD Asset Management Inc grew its stake in Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after buying an additional 371,856 shares during the last quarter. Boston Trust Walden Corp grew its stake in Amphastar Pharmaceuticals by 24.2% during the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after buying an additional 236,704 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after buying an additional 105,288 shares during the last quarter. Northern Trust Corp grew its stake in Amphastar Pharmaceuticals by 5.1% during the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company's stock worth $22,767,000 after buying an additional 29,808 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in Amphastar Pharmaceuticals by 7.1% during the 4th quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock worth $22,601,000 after buying an additional 40,212 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 10.1%

Shares of AMPH traded up $2.19 during midday trading on Friday, reaching $23.81. 1,004,809 shares of the company were exchanged, compared to its average volume of 461,231. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average price of $23.35 and a 200-day moving average price of $26.21. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 8.92 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a 1-year low of $20.39 and a 1-year high of $53.96.

Analyst Ratings Changes

AMPH has been the topic of several analyst reports. Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a report on Friday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $30.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.